Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Label Phase II Trial of Zoledronic Acid, Pravastatin, and Lonafarnib for Patients With Hutchinson-Gilford Progeria Syndrome (HGPS) and Progeroid Laminopathies

Trial Profile

An Open Label Phase II Trial of Zoledronic Acid, Pravastatin, and Lonafarnib for Patients With Hutchinson-Gilford Progeria Syndrome (HGPS) and Progeroid Laminopathies

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 25 Jul 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lonafarnib (Primary) ; Pravastatin; Zoledronic acid
  • Indications Progeria
  • Focus Therapeutic Use
  • Acronyms ProLon2
  • Most Recent Events

    • 16 Jul 2018 Planned End Date changed from 1 Jun 2018 to 1 Jul 2020.
    • 16 Jul 2018 Planned primary completion date changed from 1 Jun 2018 to 1 Jul 2019.
    • 24 Apr 2018 Results of a pooled analysis (ProLon1 and ProLon2; n=63) trials assessing the association of lonafarnib with mortality rate versus no treatment (n=103), published in the JAMA: the Journal of the American Medical Association
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top